A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements Massimiliano Bonifacio Luigi Scaffidi Mario Tiribelli CorrespondenceOpen Access26 Mar 2024 Blood Cancer Journal Volume: 14, P: 53 Clinical outcomes of patients with lymphoid blastic...
Seven instances of complete remission, confirmed by bone marrow aspiration, were observed among 202 patients with chronic lymphocytic leukemia and leukolymphosarcoma treated during a 10-year period. Review of these cases and of 10 instances reported by others revealed that complete remission of ...
During and after treatment, regular tests are necessary to monitor the patient's blood. When no leukemia is detected, patients may be able to end treatment. Even patients in treatment-free remission must be monitored regularly, for life, and work closely with a hematologist or oncologist. That ...
leukemia reaction. This clinical report presents an observation of a long remission of patient with chronic myeloid leukemia (CML) with mixed hemopoietic chymerism after allo-BMT, persisting during 78 months, which was conirmed by the results of molecular genetic studies by luorescent in situ ...
Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168:461–70. Article PubMed Google Scholar Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul ...
Relapse of chronic myeloid leukemia (CML) in chronic phase after allogeneic stem cell transplantation (SCT) can be successfully treated by donor lymphocyte infusion (DLI). However, relapse of accelerated phase CML, blast crisis, or acute leukemia after allogeneic SCT are resistant to DLI in the ...
Polymerase chain reaction (PCR) for immunoglobulin heavy chain gene was used to determine molecular remission (mCR). Twenty-nine pts (median age 64 years; range: 47–75) have been enrolled. Toxicity is reported on all, while response on 19 evaluable pts. Nine pts are inevaluable (2 ...
It has been well demonstrated that in haplo-HSCT for high-risk acute myeloid and lymphoid leukemia, donor-derived alloreactive NK cells play a crucial role in the GvL effect due to KIR–HLA mismatches between donor and patient and the consequent lack of NK inhibition by KIR ligands [29,30,...
and earlier DMR in patients with the e14a2 transcript. Keywords: chronic myeloid leukemia;BCR::ABL1transcript type;tyrosine kinase inhibitors;discontinuation;treatment free remission 1. Introduction Chronic myeloid leukemia (CML) is characterized by the presence of Philadelphia chromosome (Ph) containing ...
The recent American Society of Hematology (ASH) annual meeting, held in Orlando, Florida, in December 2019 was an exciting meeting for researchers and clinicians working in the field of chronic myeloid leukemia (CML), as well as for patients suffering from the disease. Interesting updates were ...